These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15557666)

  • 1. Acellular pertussis vaccines and complement killing of Bordetella pertussis.
    Weiss AA; Patton AK; Millen SH; Chang SJ; Ward JI; Bernstein DI
    Infect Immun; 2004 Dec; 72(12):7346-51. PubMed ID: 15557666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Specificity Following a Recent
    Raeven RHM; van der Maas L; Pennings JLA; Fuursted K; Jørgensen CS; van Riet E; Metz B; Kersten GFA; Dalby T
    Front Immunol; 2019; 10():1364. PubMed ID: 31275314
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine.
    Dalby T; Petersen JW; Harboe ZB; Krogfelt KA
    J Med Microbiol; 2010 Sep; 59(Pt 9):1029-1036. PubMed ID: 20508003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of (antibody-dependent) complement-mediated serum killing in protection against Bordetella pertussis.
    Geurtsen J; Fae KC; van den Dobbelsteen GP
    Expert Rev Vaccines; 2014 Oct; 13(10):1229-40. PubMed ID: 25081731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine.
    Edelman KJ; He Q; Makinen JP; Haanpera MS; Tran Minh NN; Schuerman L; Wolter J; Mertsola JA
    Clin Infect Dis; 2004 Jul; 39(2):179-85. PubMed ID: 15307026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults.
    Weingart CL; Keitel WA; Edwards KM; Weiss AA
    Infect Immun; 2000 Dec; 68(12):7175-9. PubMed ID: 11083851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
    Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
    Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007.
    Hallander H; Advani A; Alexander F; Gustafsson L; Ljungman M; Pratt C; Hall I; Gorringe AR
    Clin Vaccine Immunol; 2014 Feb; 21(2):165-73. PubMed ID: 24307240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease.
    Alexander F; Matheson M; Fry NK; Labram B; Gorringe AR
    Clin Vaccine Immunol; 2012 Nov; 19(11):1776-83. PubMed ID: 22956654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
    Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG
    J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay.
    Fry NK; Litt DJ; Duncan J; Vaghji L; Warrener L; Samuel D; Andrews N; Harnden A; Harrison TG
    J Med Microbiol; 2013 Sep; 62(Pt 9):1281-1289. PubMed ID: 23722435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines.
    Christy C; Pichichero ME; Reed GF; Decker MD; Anderson EL; Rennels MB; Englund JA; Edwards KM; Steinhoff MC
    Pediatrics; 1995 Sep; 96(3 Pt 2):584-7. PubMed ID: 7659481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bordetella pertussis fimbriae (Fim): relevance for vaccines.
    Gorringe AR; Vaughan TE
    Expert Rev Vaccines; 2014 Oct; 13(10):1205-14. PubMed ID: 25102891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens.
    van den Berg BM; David S; Beekhuizen H; Mooi FR; van Furth R
    Vaccine; 2000 Dec; 19(9-10):1118-28. PubMed ID: 11137247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
    Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
    Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.
    Meyer CU; Zepp F; Decker M; Lee M; Chang SJ; Ward J; Yoder S; Bogaert H; Edwards KM
    Clin Vaccine Immunol; 2007 Mar; 14(3):288-92. PubMed ID: 17267589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.